Probatebeta
Target

RET

Proto-oncogene tyrosine-protein kinase receptor Ret

As of the edition of 20 October 2026, RET (proto-oncogene tyrosine-protein kinase receptor Ret, UniProt P07949) has 19 drugs tested at it and 18 companies on the list, 3 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P07949
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
34
Disease areas
Cancer; Digestive system; Lungs and airways; Blood and lymph; Hormones; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue
Registered trials of its drugs
542

Drugs at this target

StatusCount
Marketed6
Active4
Went quiet3
Stopped1
Status not established5
Total19
DrugStatusFurthest phaseUS protection
RegorafenibMarketedPhase 4Ends 2032
VandetanibMarketedPhase 3none listed
AlectinibMarketedPhase 4Ends 2031
QuizartinibMarketedPhase 3Ends 2030
SelpercatinibMarketedPhase 4Ends 2038
PralsetinibMarketedPhase 4Ends 2042
LestaurtinibActivePhase 3none listed
CEP-32496Went quietPhase 1none listed
HS-10365ActivePhase 2none listed
BOS-589Went quietPhase 2none listed
GSK-3179106Went quietPhase 1none listed
LOXO-260Status not establishedPhase 1none listed

12 of 19 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A3
Route B6
Engaged3
Undetermined6
Total on the list18
Three companies on route A or B, with the route only
CompanyRoute
Eli LillyRoute B
Bristol Myers SquibbRoute A
Daiichi SankyoRoute B

The other 15 companies at RET

In the product

18 companies in all; 15 are not named here, and no score is.

See the 18 companies at RET, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at RET

Other targets in cancer

Companies holding approvals at RET